FP
CNCE

Foundry Partners’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Foundry Partners’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-37,092
Closed -$466K – 398
2018
Q4 		$466K Sell
37,092
-63
-0.2% -$870 0.02% 343
2018
Q3 		$551K Sell
37,155
-57
-0.2% -$897 0.02% 344
2018
Q2 		$626K Buy
+37,212
New +$723K 0.03% 337

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Foundry Partners's CNCE Position: Q1 2019 in Review

Foundry Partners sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2019, closing a stake of 37,092 shares — an estimated $466K sold.

Foundry Partners first reported a position in CNCE in Q2 2018 and held it in 3 quarters. The position peaked at $626K in Q2 2018. 92 funds tracked by Wall St. Rank hold CNCE as of Q1 2019.

  • Foundry Partners reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Foundry Partners sold 37,092 Concert Pharmaceuticals, Inc. shares in Q1 2019, an estimated $466K.
  • Foundry Partners first reported a position in Concert Pharmaceuticals, Inc. in Q2 2018 and held it in 3 quarters.
  • Foundry Partners's Concert Pharmaceuticals, Inc. position peaked at $626K in Q2 2018.
  • 92 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2019.

Based on Foundry Partners's 13F filing for Q1 2019, filed 22 Apr 2019.